AI assistant
Jade Biosciences, Inc. — Director's Dealing 2021
Jun 30, 2021
33383_dirs_2021-06-29_1089c4b4-6dab-4ce4-8444-6bd3d16e613f.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: Aerovate Therapeutics, Inc. (AVTE)
CIK: 0001798749
Period of Report: 2021-06-29
Reporting Person: Dake Benjamin T (See Remarks)
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Stock Option (Right to Buy) | $1.74 | 2030-09-03 | Common Stock (48293) | Direct | |
| Stock Option (Right to Buy) | $1.74 | 2030-09-03 | Common Stock (72325) | Direct | |
| Stock Option (Right to Buy) | $2.144 | 2031-04-01 | Common Stock (48882) | Direct | |
| Stock Option (Right to Buy) | $2.144 | 2031-04-01 | Common Stock (328921) | Direct |
Footnotes
F1: 10% of this option vested and became exercisable on January 1, 2020, with an additional 22.5% vested on January 1, 2021 and the remainder vesting in 36 monthly installments thereafter.
F2: 25% of this option shall vest and become exercisable on August 1, 2021, with the remainder vesting in 36 substantially equal monthly installments thereafter.
F3: This option shall vest in 48 substantially equal monthly installments, with the first installment vested on May 2, 2021.
F4: This option shall vest in 48 substantially equal monthly installments, with the first installment vesting on July 4, 2021.